NCT03124524 is a Phase 4 clinical trial of estradiol valerate/dienogest in Primary Dysmenorrhea, sponsored by Adana Numune Training and Research Hospital.

Who is sponsoring NCT03124524?

NCT03124524 is sponsored by Adana Numune Training and Research Hospital.

What drugs are being tested in NCT03124524?

Interventions in NCT03124524: estradiol valerate/dienogest, ethinylestradiol and drospirenone.

What condition does NCT03124524 study?

NCT03124524 studies Primary Dysmenorrhea.

Is NCT03124524 still recruiting?

NCT03124524 is currently completed. Last updated 26 April 2017.

Last reviewed 2017-04-26 · How we verify

NCT03124524

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment Choice in Primary Dysmenorrhea

Completed Phase 4 Last updated 26 April 2017

What this trial tests

Phase 4 trial testing estradiol valerate/dienogest in Primary Dysmenorrhea in 99 participants. Completed in 10 October 2016.

Timeline

15 January 2015

Primary endpoint
20 September 2016

10 October 2016

Quick facts

Lead sponsor	Adana Numune Training and Research Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	99
Start date	15 January 2015
Primary completion	20 September 2016
Estimated completion	10 October 2016

Drugs / interventions tested

estradiol valerate/dienogest
ethinylestradiol and drospirenone — full drug profile →

Conditions studied

Primary Dysmenorrhea — all drugs for Primary Dysmenorrhea →

Sponsor

Adana Numune Training and Research Hospital

Who can join

Adults 18 to 35, female only, with Primary Dysmenorrhea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our aim is to evaluate and compare the pain relief of estradiol valerate/dienogest and ethinylestradiol/ drospirenone by using doppler indices. 100 nullipara patients with symptoms of severe primary dysmenorrhea (PD) requesting contraception aged from 18 to 35 were included to the study. Visual analog scale (VAS), the uterine artery doppler indices including systole/diastole rates ( S/D), pulsatility index (PI) and resistance index (RI) values were evaluated and recorded in both uterine vessels before treatment. The 66 PD patients who met the inclusion criteria were divided into 2 groups and 33 healthy controls created Group 1. Group 2 were administered estradiol valerate/dienogest while Group 3 were administered 0.03 mg ethinylestradiol and 3 mg drospirenone. Both VAS scores and doppler indices were repeated after 3 months treatment. The changes in values were recorded.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Combined oral contraceptive pill for primary dysmenorrhoea.
Schroll JB, Black AY, Farquhar C, Chen I. · · 2023 · cited 16× · PMID 37523477 · DOI 10.1002/14651858.cd002120.pub4
A comparison of two different oral contraceptives in patients with severe primary dysmenorrhoea.
Uysal G, Akkaya H, Cagli F, Tutus S, et al · · 2018 · cited 12× · PMID 29537325 · DOI 10.1080/01443615.2017.1410533

Verify or expand the search:

Other recruiting trials for Primary Dysmenorrhea

Currently open trials in the same condition.

NCT07409337 — Self-Acupressure for Primary Dysmenorrhea and Premenstrual Symptoms · NA · recruiting
NCT06995287 — Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Severe Primary Dysme · Phase 3 · recruiting
NCT07352982 — Transcutaneous Tibial Nerve Stimulation on Women With Primary Dysmenorrhea · NA · recruiting
NCT07239232 — "Knee Joint Position Sense and Dynamic Balance in Females With Primary Dysmenorrhea · recruiting
NCT07314021 — Primary Dysmenorrhea and Mobilization. · NA · active not recruiting

Other Adana Numune Training and Research Hospital trials

Trials by the same sponsor.

NCT04064801 — Red Cell Distribution Width as a Predictor of Mortality in Acute Methanol Poisoning · completed
NCT04397081 — Atopic Diseases & Human Papilloma Virus · completed
NCT03127293 — Hyperemesis Gravidarum and Osteoporosis · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03124524 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Adana Numune Training and Research Hospital
Last refreshed: 26 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03124524.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing